Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ
Closed
Oct 23, 2026
Day's Range
16.8152 wk Range
11.48Overview - AUPH - Aurinia Pharmaceuticals Inc.
Key Statistics
Valuation
Enterprise Value
1.86B
P/E (Trailing)
7.39
P/E (Forward)
14.43
PEG Ratio
0.09
Price / Sales (TTM)
7.20
Price / Book
3.64
EV / EBITDA
10.36
Profitability
Gross Margin
92.12%
Profit Margin
100.83%
Operating Margin
55.68%
Return on Assets
15.48%
Return on Equity
66.11%
Ownership
Shares Outstanding
132.90M
Float
129.21M
Short % of Shares Outstanding
6.57%
Held by Insiders
6.79%
Held by Institutions
60.59%
Price stats
Beta
1.61
50-Day Avg
16.37
200-Day Avg
15.60
Dividends
Payout Ratio
0.00%
Analyst Consensus
7 analysts
Shariah Compliance
Report Date: Feb 17, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - AUPH - Aurinia Pharmaceuticals Inc.
Peers - AUPH - Aurinia Pharmaceuticals Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- AUPHNASDAQAurinia Pharmaceuticals Inc.2.24BMarket Cap+27.11%52-week change7.39P/E (Trailing)100.83%Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)32.26%Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)16.12%Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.13BMarket Cap-20.35%52-week change160.80P/E (Trailing)-63.63%Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.01BMarket Cap+16.49%52-week change18.23P/E (Trailing)70.84%Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)-97.02%Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.58BMarket Cap+1.57%52-week change147.76P/E (Trailing)2.14%Profit Margin
Profile Summary - AUPH - Aurinia Pharmaceuticals Inc.
About
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on therapies for autoimmune diseases with high unmet medical need. Aurinia Pharmaceuticals develops and commercializes LUPKYNIS, an oral treatment for adults with active lupus nephritis, a serious kidney complication associated with systemic lupus…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
